How little Denmark got homegrown giant Novo Nordisk to lower Ozempic prices
Pharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen production
Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Ozempic's sales success reflects its unintended role as a weight-loss drug, boosting Novo Nordisk's valuation despite regulatory challenges.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic prices
Pharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen production
Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Ozempic's sales success reflects its unintended role as a weight-loss drug, boosting Novo Nordisk's valuation despite regulatory challenges.
Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony
Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profits
Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economy
Denmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
Denmark gets Novo Nordisk to lower Ozempic prices
Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony
Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profits
Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economy
Denmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
New Study Finds Wegovy Reduces COVID Death Risk By 33 Percent
Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing
The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?
The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.
Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
Bernie Sanders grills Ozempic maker over high prices
Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Novo Nordisk's Wegovy sales jump on international rollouts
Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.
Novo's main Ozempic plant cited for quality lapses by FDA
Novo Nordisk's plant in Denmark is facing FDA quality issues, impacting supply of popular diabetes and obesity medications Ozempic and Wegovy.
New Study Finds Wegovy Reduces COVID Death Risk By 33 Percent
Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing
The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?
The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.
Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
Bernie Sanders grills Ozempic maker over high prices
Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Novo Nordisk's Wegovy sales jump on international rollouts
Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.
Novo's main Ozempic plant cited for quality lapses by FDA
Novo Nordisk's plant in Denmark is facing FDA quality issues, impacting supply of popular diabetes and obesity medications Ozempic and Wegovy.
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEO
The U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
The next big market for weight-loss drugs: children
Novo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions
Many patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.
Sen. Bernie Sanders launches Senate investigation into 'high' pricing of Ozempic, Wegovy
Sen. Bernie Sanders investigating high drug prices for Ozempic and Wegovy.
Senate Committee Investigates Ozempic and Wegovy Costs
The Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this year
Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this year
Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
Study shows no evidence of suicidal thoughts caused by Ozempic, Wegovy
A large U.S. study found no evidence of a link between Novo Nordisk's Ozempic and Wegovy and an increase in suicidal thoughts.
The study found that semaglutide, the active ingredient in Ozempic and Wegovy, actually had a lower risk of new and recurrent suicidal thoughts compared to other medications for weight loss or diabetes.
Ozempic and Wegovy could soon be challenged by China's generic competitors
Intensifying competition in Chinese market for Novo Nordisk's diabetes drug Ozempic and weight loss treatment Wegovy.